第二队
安德鲁鲍姆＆团队摩根士丹利
摩根士丹利的四名成员团队在Andrew Baum的指导下花了过去四年在亚军的位置，但今年跃入了第2号。The researchers deserve “top marks for conviction and flexibility,” in the words of one investor impressed with the team’s uncharacteristic downgrade of long-term favorite Roche Holding, which the analysts had been urging clients to overweight since 2006. In September, after the U.S. Food and Drug Administration announced that it was extending its review of the Basel conglomerate’s breast cancer treatment drug Avastin, the analysts downgraded the stock to neutral, at Sf138. In December the FDA announced that it was “recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use.” By the end of that month, Roche’s stock had barely moved, ending the year at Sf137.